Proteome Sciences PLC AGM Statement and Q1 Trading Update (5458X)
30 Abril 2019 - 8:30AM
UK Regulatory
TIDMPRM
RNS Number : 5458X
Proteome Sciences PLC
30 April 2019
30 April 2019
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting (AGM) Statement and Q1 Trading Update
At the Company's AGM being held today at 2.30 pm the Chairman,
Christopher Pearce, will make the following statement:
"As indicated in our recent results, we remain optimistic about
the future, with the near-term availability of higher-plex TMT(R)
set to add significant value to this asset, and the utility of
quantitative proteomics increasing in response to diagnostic
advances and disruptive technologies. We are pleased to report a
good first quarter, with further growth in sales and royalties from
TMT(R) and an improving services business continuing the trend in
orders and revenues established during the latter part of
2018."
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKKDNFBKKPQN
(END) Dow Jones Newswires
April 30, 2019 09:30 ET (13:30 GMT)
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024